Arcutis Biotherapeutics Stock Earnings Reports

Arcutis reported strong Q1 2026 performance driven by ZORYVE, with net product revenues of $105.4M (up 65% year-over-year) despite typical Q1 seasonality and severe weather headwinds. Management reiterated full-year revenue guidance of $480M–$495M and expects quarter-on-quarter demand growth for the rest of 2026, supported by improving gross-to-net (guided to remain in the low-to-mid 50s by year end), expanding prescription trends (≈21k Rxs/week on a rolling 4-week basis), and market-share gains within branded non-steroidal topical prescriptions (48% share). Commercial investments include completion of the dermatology sales force expansion (new reps in the field now), building a targeted primary care/pediatric franchise (head hired, expected field launch in Q3 with impact beginning late 2026/2027), and ongoing DTC campaigns. Clinical progress: sNDA submitted for ZORYVE 0.05% cream in infants 3–24 months for atopic dermatitis (fast 3-month submission post topline), MUSE trial enrollment completed for ZORYVE foam 0.3% in children 2–11 with scalp/body psoriasis, near-full enrollment in Phase II vitiligo POC trial (readout expected Q4 2026), ongoing HS POC (readout expected Q1 2027), and Phase I initiation of ARQ-234 (CD200R agonist) with SAD ongoing and MAD + PoC planned. Financials: positive operating cash flow maintained (net cash provided by operating activities of $2.2M in Q1), cash + marketable securities of $224.3M, total debt $101.5M and an additional $50M undrawn facility, increased R&D spending (notably a $10M milestone related to ARQ-234), and moderate SG&A increases as commercialization investments continue. Management emphasized discipline in reinvesting ZORYVE-generated cash to drive a sales inflection and operating leverage expansion in 2027 and beyond.